marketcaparena
Search

    COLL

    COLLEGIUM PHARMACEUTICAL, INC

    Company overview

    Market capitalization
    $736.73M
    Employees
    423
    Latest publication
    2026-09-29
    About COLLEGIUM PHARMACEUTICAL, INC

    Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue199,878,000USD193,520,000USD205,449,000USD209,361,000USD188,000,000USD177,757,000USD181,949,000USD159,301,000USD
    Cost Of Revenue89,586,000USD76,274,000USD77,071,000USD80,190,000USD79,616,000USD80,433,000USD83,661,000USD62,507,000USD
    Gross Profit110,292,000USD117,246,000USD128,378,000USD129,171,000USD108,384,000USD97,324,000USD98,288,000USD96,794,000USD
    Selling General Administrative106,594,000USD86,350,000USD67,640,000USD67,103,000USD73,637,000USD76,423,000USD47,985,000USD61,955,000USD
    Other Operating Expenses62,953,000USD———————
    Total Operating Expenses106,594,000USD85,281,000USD69,154,000USD65,551,000USD73,279,000USD75,637,000USD60,177,000USD61,955,000USD
    Operating Income3,698,000USD31,965,000USD59,224,000USD63,620,000USD35,105,000USD21,687,000USD38,111,000USD34,839,000USD
    Total Other Income Expense Net-17,230,000USD-13,225,000USD-30,188,000USD-20,184,000USD-18,080,000USD-18,565,000USD-20,842,000USD-19,259,000USD
    Interest Expense19,519,000USD15,862,000USD104,794,000USD21,767,000USD20,463,000USD20,790,000USD22,654,000USD18,394,000USD
    Income Before Tax-13,532,000USD18,740,000USD29,036,000USD43,436,000USD17,025,000USD3,122,000USD17,269,000USD15,580,000USD
    Income Tax Expense1,519,000USD4,244,000USD12,073,000USD11,929,000USD5,042,000USD705,000USD4,733,000USD6,245,000USD
    Net Income-15,051,000USD14,496,000USD16,963,000USD31,507,000USD11,983,000USD2,417,000USD12,536,000USD9,335,000USD
    Unclassified Operating Expenses—-1,069,000USD1,514,000USD-1,552,000USD——1,529,000USD—
    Interest Income—3,706,000USD3,565,000USD3,116,000USD2,383,000USD2,225,000USD1,812,000USD3,280,000USD
    Net Interest Income—-12,156,000USD-15,727,000USD-18,651,000USD-18,080,000USD-18,565,000USD-20,842,000USD-15,114,000USD
    Tax Provision—4,244,000USD12,073,000USD11,929,000USD5,042,000USD705,000USD4,733,000USD6,245,000USD
    Net Income From Continuing Ops—14,496,000USD16,963,000USD31,507,000USD11,983,000USD2,417,000USD12,536,000USD9,335,000USD
    Ebit—34,602,000USD133,830,000USD65,203,000USD37,488,000USD23,912,000USD39,923,000USD33,974,000USD
    Ebitda—90,538,000USD303,566,000USD121,709,000USD94,096,000USD80,476,000USD96,435,000USD75,721,000USD
    Depreciation And Amortization—55,936,000USD169,736,000USD56,506,000USD56,608,000USD56,564,000USD56,512,000USD41,747,000USD
    Reconciled Depreciation—55,936,000USD56,396,000USD56,506,000USD56,608,000USD56,564,000USD56,512,000USD41,747,000USD
    Selling And Marketing Expenses——————10,663,000USD—
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20162016-12-31 · USDFY 20152015-12-31 · USD
    Total Revenue780,567,000USD631,449,000USD566,767,000USD463,933,000USD276,868,000USD310,016,000USD1,711,000USD0USD
    Cost Of Revenue317,310,000USD254,105,000USD240,598,000USD254,445,000USD126,251,000USD130,180,000USD213,000USD171,000USD
    Gross Profit463,257,000USD377,344,000USD326,169,000USD209,488,000USD150,617,000USD179,836,000USD1,498,000USD-171,000USD
    Selling General Administrative284,803,000USD172,320,000USD151,802,000USD160,443,000USD114,774,000USD108,464,000USD80,632,000USD18,932,000USD
    Unclassified Operating Expenses-8,630,000USD24,466,000USD——4,578,000USD———
    Total Operating Expenses276,173,000USD207,449,000USD159,208,000USD176,169,000USD132,989,000USD123,604,000USD95,580,000USD26,907,000USD
    Operating Income187,084,000USD169,895,000USD166,961,000USD33,319,000USD17,628,000USD56,232,000USD-94,082,000USD-26,907,000USD
    Interest Income11,289,000USD13,976,000USD15,615,000USD1,047,000USD12,000USD232,000USD94,000USD—
    Interest Expense82,312,000USD73,974,000USD83,339,000USD63,213,000USD21,014,000USD28,882,000USD94,000USD439,000USD
    Net Interest Income-71,023,000USD-59,998,000USD-67,724,000USD-62,166,000USD-21,002,000USD-28,650,000USD-94,000USD—
    Income Before Tax92,619,000USD98,568,000USD75,733,000USD-28,847,000USD-3,374,000USD27,582,000USD-94,176,000USD-27,255,000USD
    Income Tax Expense29,749,000USD29,378,000USD27,578,000USD-3,845,000USD-74,891,000USD830,000USD94,000USD-91,000USD
    Tax Provision29,749,000USD29,378,000USD27,578,000USD-3,845,000USD-74,891,000USD830,000USD——
    Net Income62,870,000USD69,190,000USD48,155,000USD-25,002,000USD71,517,000USD26,752,000USD-94,176,000USD-27,255,000USD
    Net Income From Continuing Ops62,870,000USD69,190,000USD48,155,000USD-25,002,000USD71,517,000USD26,752,000USD-94,176,000USD-27,255,000USD
    Ebit174,931,000USD172,542,000USD159,072,000USD34,366,000USD17,640,000USD56,464,000USD-94,082,000USD-26,907,000USD
    Ebitda401,005,000USD341,702,000USD308,328,000USD173,305,000USD86,557,000USD118,014,000USD-93,427,000USD-26,736,000USD
    Depreciation And Amortization226,074,000USD169,160,000USD149,256,000USD138,939,000USD68,917,000USD61,550,000USD655,000USD171,000USD
    Reconciled Depreciation226,074,000USD169,160,000USD149,256,000USD138,939,000USD68,917,000USD61,550,000USD——
    Total Other Income Expense Net-94,465,000USD-71,327,000USD-91,228,000USD-62,166,000USD-21,002,000USD-28,650,000USD-94,000USD-348,000USD
    Research Development—0USD0USD3,983,000USD9,451,000USD9,772,000USD14,948,000USD7,975,000USD
    Selling And Marketing Expenses—10,663,000USD7,406,000USD11,743,000USD4,186,000USD5,368,000USD——
    Non Operating Income Net Other———1,047,000USD12,000USD232,000USD-94,000USD-348,000USD
    Net Income Applicable To Common Shares———-25,002,000USD71,517,000USD26,752,000USD-94,176,000USD-27,255,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets2,135,790,000USD1,651,955,000USD1,656,834,000USD1,607,328,000USD1,592,631,000USD1,631,388,000USD1,663,591,000USD1,635,154,000USD
    Cash And Equivalents129,467,000USD———————
    Cash And Short Term Investments129,467,000USD421,753,000USD406,529,000USD305,713,000USD222,153,000USD197,774,000USD162,763,000USD119,957,000USD
    Short Term Investments0USD153,105,000USD155,427,000USD135,767,000USD104,805,000USD101,582,000USD92,198,000USD80,997,000USD
    Total Current Assets608,014,000USD745,668,000USD691,411,000USD613,870,000USD549,211,000USD527,553,000USD482,257,000USD443,810,000USD
    Other Current Assets60,326,000USD52,412,000USD32,642,000USD36,156,000USD75,887,000USD63,851,000USD55,394,000USD57,365,000USD
    Other Non Current Assets15,237,000USD———————
    Total Liabilities1,823,881,000USD———————
    Total Current Liabilities589,861,000USD434,973,000USD440,028,000USD452,929,000USD464,609,000USD486,710,000USD509,510,000USD459,426,000USD
    Other Current Liabilities71,250,000USD———————
    Total Stockholder Equity311,909,000USD312,422,000USD301,675,000USD274,808,000USD232,206,000USD234,434,000USD228,842,000USD234,279,000USD
    Total Equity Including Noncontrolling Interest311,909,000USD———————
    Long Term Debt797,824,000USD770,195,000USD780,325,000USD743,533,000USD758,336,000USD773,127,000USD787,905,000USD802,627,000USD
    Deferred Revenue667,000USD———————
    Deferred Revenue Non Current8,778,000USD———————
    Net Receivables285,102,000USD228,762,000USD211,328,000USD233,949,000USD213,023,000USD228,710,000USD228,540,000USD228,456,000USD
    Inventory113,269,000USD42,741,000USD40,912,000USD38,052,000USD38,148,000USD37,218,000USD35,560,000USD38,032,000USD
    Property Plant Equipment Net14,444,000USD15,636,000USD16,200,000USD16,681,000USD18,166,000USD19,395,000USD20,151,000USD20,783,000USD
    Goodwill190,177,000USD———————
    Intangible Assets1,186,084,000USD614,037,000USD669,510,000USD724,983,000USD780,456,000USD835,930,000USD891,402,000USD946,875,000USD
    Accounts Payable9,241,000USD6,828,000USD10,659,000USD7,647,000USD10,890,000USD17,853,000USD3,934,000USD3,142,000USD
    Short Term Debt55,000,000USD34,074,000USD30,407,000USD65,955,000USD65,921,000USD65,887,000USD65,854,000USD65,854,000USD
    Common Stock41,000USD41,000USD41,000USD41,000USD40,000USD40,000USD40,000USD40,000USD
    Retained Earnings-101,684,000USD-86,633,000USD-101,129,000USD-118,092,000USD-149,599,000USD-161,582,000USD-163,999,000USD-176,535,000USD
    Accumulated Other Comprehensive Income0USD-219,000USD319,000USD292,000USD337,000USD241,000USD55,000USD393,000USD
    Total Liab—1,339,533,000USD1,355,159,000USD1,332,520,000USD1,360,425,000USD1,396,954,000USD1,434,749,000USD1,400,875,000USD
    Other Current Liab—393,404,000USD398,295,000USD378,660,000USD378,526,000USD375,582,000USD414,537,000USD384,458,000USD
    Capital Stock—41,000USD41,000USD41,000USD40,000USD40,000USD40,000USD40,000USD
    Good Will—145,925,000USD145,925,000USD145,925,000USD147,936,000USD150,760,000USD162,333,000USD145,959,000USD
    Cash—268,648,000USD251,102,000USD169,946,000USD117,348,000USD96,192,000USD70,565,000USD38,960,000USD
    Current Deferred Revenue—667,000USD667,000USD667,000USD—10,000,000USD10,000,000USD34,928,000USD
    Net Debt—539,408,000USD689,456,999USD766,322,000USD711,762,000USD748,021,000USD788,733,000USD835,435,000USD
    Short Long Term Debt—32,625,000USD29,000,000USD64,583,000USD64,583,000USD64,583,000USD64,583,000USD64,583,000USD
    Short Long Term Debt Total—808,056,000USD940,558,999USD936,268,000USD829,110,000USD844,213,000USD859,298,000USD874,395,000USD
    Property Plant Equipment Gross—15,636,000USD32,742,000USD16,681,000USD18,166,000USD19,395,000USD33,685,000USD20,783,000USD
    Common Stock Shares Outstanding—40,065,665shares39,701,693shares39,439,890shares39,075,703shares32,840,153shares40,109,649shares40,163,266shares
    Non Current Assets Total—906,287,000USD965,423,000USD993,458,000USD1,043,420,000USD1,103,835,000USD1,181,334,000USD1,191,344,000USD
    Non Current Liabilities Total—904,560,000USD915,131,000USD879,591,000USD895,816,000USD910,244,000USD925,239,000USD941,449,000USD
    Non Currrent Assets Other—17,122,000USD20,193,000USD2,338,000USD4,895,000USD6,085,000USD9,415,000USD5,218,000USD
    Net Working Capital—310,695,000USD251,383,000USD160,941,000USD84,602,000USD40,843,000USD-27,253,000USD-15,616,000USD
    Unclassified Non Current Assets—113,567,000USD45,393,000USD103,531,000USD91,967,000USD91,665,000USD42,639,000USD72,509,000USD
    Unclassified Current Liabilities—-32,625,000USD-29,000,000USD-64,583,000USD-55,311,000USD-47,195,000USD-49,398,000USD-93,539,000USD
    Unclassified Non Current Liabilities—134,365,000USD134,806,000USD136,058,000USD137,480,000USD136,721,000USD136,152,000USD134,726,000USD
    Unclassified Equity—399,192,000USD402,403,000USD392,526,000USD381,388,000USD395,695,000USD392,706,000USD410,341,000USD
    Other Assets——68,202,000USD———55,394,000USD—
    Non Current Liabilities Other—————396,000USD1,182,000USD4,096,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets1,656,834,000USD1,663,591,000USD1,143,308,000USD1,174,131,000USD692,077,000USD643,841,000USD306,302,000USD291,245,000USD
    Intangible Assets669,510,000USD891,402,000USD421,708,000USD567,468,000USD268,723,000USD335,904,000USD29,503,000USD44,255,000USD
    Other Current Assets32,642,000USD55,394,000USD93,000USD16,681,000USD5,879,000USD4,838,000USD3,105,000USD5,116,000USD
    Total Liab1,355,159,000USD1,434,749,000USD947,877,000USD979,289,000USD489,149,000USD457,810,000USD218,870,000USD199,660,000USD
    Total Stockholder Equity301,675,000USD228,842,000USD195,431,000USD194,842,000USD202,928,000USD186,031,000USD87,432,000USD91,585,000USD
    Other Current Liab398,295,000USD424,537,000USD264,902,000USD262,268,000USD223,018,000USD179,393,000USD191,029,000USD175,334,000USD
    Common Stock41,000USD40,000USD38,000USD37,000USD36,000USD35,000USD34,000USD33,000USD
    Capital Stock41,000USD40,000USD38,000USD37,000USD36,000USD35,000USD34,000USD33,000USD
    Retained Earnings-101,129,000USD-163,999,000USD-233,189,000USD-281,344,000USD-256,342,000USD-333,147,000USD-359,899,000USD-337,177,000USD
    Good Will145,925,000USD162,333,000USD133,857,000USD133,695,000USD0USD———
    Cash251,102,000USD70,565,000USD238,947,000USD173,688,000USD186,426,000USD174,116,000USD170,019,000USD146,633,000USD
    Cash And Short Term Investments406,529,000USD162,763,000USD310,548,000USD173,688,000USD186,426,000USD174,116,000USD170,019,000USD146,633,000USD
    Total Current Assets691,411,000USD482,257,000USD537,600,000USD419,989,000USD315,543,000USD277,888,000USD255,720,000USD237,512,000USD
    Total Current Liabilities440,028,000USD509,510,000USD457,915,000USD433,726,000USD279,566,000USD239,451,000USD201,765,000USD187,484,000USD
    Current Deferred Revenue667,000USD10,000,000USD-16,010,000USD—————
    Net Debt689,456,999USD788,733,000USD435,336,000USD535,487,000USD72,324,000USD92,468,000USD-148,425,000USD-135,133,000USD
    Short Term Debt30,407,000USD65,854,000USD184,321,000USD163,612,000USD49,167,000USD48,225,000USD4,489,000USD1,642,000USD
    Short Long Term Debt29,000,000USD64,583,000USD183,333,000USD162,500,000USD48,353,000USD47,495,000USD3,833,000USD1,642,000USD
    Short Long Term Debt Total940,558,999USD859,298,000USD674,283,000USD709,175,000USD258,750,000USD266,584,000USD21,594,000USD11,500,000USD
    Long Term Debt780,325,000USD787,905,000USD483,838,000USD538,451,000USD201,632,000USD209,594,000USD7,667,000USD9,858,000USD
    Short Term Investments155,427,000USD92,198,000USD71,601,000USD0USD————
    Net Receivables211,328,000USD228,540,000USD179,525,000USD183,119,000USD105,844,000USD83,320,000USD72,953,000USD77,946,000USD
    Inventory40,912,000USD35,560,000USD32,332,000USD46,501,000USD17,394,000USD15,614,000USD9,643,000USD7,817,000USD
    Accounts Payable10,659,000USD3,934,000USD8,692,000USD3,494,000USD4,189,000USD10,016,000USD6,247,000USD12,150,000USD
    Property Plant Equipment Net16,200,000USD20,151,000USD22,012,000USD26,382,000USD27,135,000USD27,379,000USD20,901,000USD9,274,000USD
    Property Plant Equipment Gross32,742,000USD33,685,000USD31,690,000USD26,382,000USD27,135,000USD27,379,000USD20,901,000USD9,274,000USD
    Accumulated Other Comprehensive Income319,000USD55,000USD14,000USD0USD0USD0USD-2,288,000USD-1,837,000USD
    Common Stock Shares Outstanding39,701,693shares40,424,180shares41,788,125shares33,829,495shares41,045,805shares35,151,353shares33,453,843shares32,953,808shares
    Non Current Assets Total965,423,000USD1,181,334,000USD605,708,000USD754,142,000USD376,534,000USD365,953,000USD50,582,000USD53,733,000USD
    Non Current Liabilities Total915,131,000USD925,239,000USD489,962,000USD545,563,000USD209,583,000USD218,359,000USD17,105,000USD12,176,000USD
    Non Currrent Assets Other20,193,000USD9,415,000USD825,001USD100,000USD87,000USD2,670,000USD178,000USD204,000USD
    Net Working Capital251,383,000USD-27,253,000USD79,685,000USD-13,737,000USD85,144,000USD38,437,000USD53,955,000USD48,386,000USD
    Unclassified Non Current Assets113,595,000USD98,033,000USD27,305,999USD—-862,150,000USD———
    Unclassified Current Liabilities-29,000,000USD-59,398,000USD-183,333,000USD-158,148,000USD-45,161,000USD-45,678,000USD-3,833,000USD-3,284,000USD
    Unclassified Non Current Liabilities134,806,000USD136,152,000USD6,124,000USD—————
    Unclassified Equity402,403,000USD392,706,000USD428,530,000USD476,112,000USD502,059,000USD519,108,000USD449,551,000USD430,533,000USD
    Non Current Liabilities Other—1,182,000USD—7,112,000USD7,951,000USD8,765,000USD9,438,000USD676,000USD
    Unclassified Current Assets——15,102,000USD—————
    Other Assets———19,328,000USD942,739,000USD11,061USD178,000USD204,000USD
    Net Tangible Assets———-506,321,000USD-65,795,000USD-149,873,000USD57,929,000USD47,330,000USD
    Treasury Stock————-42,861,000USD———
    Other Liab———————676,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income14,496,000USD16,963,000USD31,507,000USD11,983,000USD2,417,000USD12,536,000USD9,335,000USD19,606,000USD
    Depreciation55,295,000USD59,448,000USD56,506,000USD56,608,000USD56,564,000USD56,512,000USD41,747,000USD35,467,000USD
    Stock Based Compensation10,880,000USD9,753,000USD9,811,000USD10,818,000USD11,524,000USD7,596,000USD7,317,000USD10,012,000USD
    Other Non Cash Items1,262,000USD13,125,000USD1,249,000USD1,808,000USD1,136,000USD1,347,000USD5,289,000USD8,043,000USD
    Change To Account Receivables-17,434,000USD22,621,000USD-20,926,000USD15,679,000USD-170,000USD106,000USD-190,000USD-9,162,000USD
    Change To Inventory-1,829,000USD-2,861,000USD96,000USD-930,000USD-1,658,000USD2,472,000USD6,985,000USD3,414,000USD
    Change In Working Capital-23,852,000USD33,831,000USD-8,503,000USD-5,864,000USD-15,704,000USD16,809,000USD-63,954,000USD-2,217,000USD
    Total Cash From Operating Activities57,113,000USD123,048,000USD78,438,000USD72,439,000USD55,398,000USD84,644,000USD-8,999,000USD67,398,000USD
    Capital Expenditures-270,000USD-689,000USD-188,000USD-65,000USD-798,000USD-570,000USD-244,000USD-270,000USD
    Free Cash Flow56,843,000USD122,359,000USD78,250,000USD72,374,000USD54,600,000USD84,074,000USD-9,243,000USD67,128,000USD
    Investments1,897,000USD-19,380,000USD-30,868,000USD-2,915,000USD-9,680,000USD-11,762,000USD-248,963,000USD-8,906,000USD
    Total Cashflows From Investing Activities1,627,000USD-20,069,000USD-30,868,000USD-2,915,000USD-9,680,000USD-11,762,000USD-248,963,000USD-8,906,000USD
    Net Borrowings-7,250,000USD-21,945,000USD-16,146,000USD-16,146,000USD-16,146,000USD-16,146,000USD148,550,000USD—
    Total Cash From Financing Activities-21,342,000USD-21,821,000USD-14,818,000USD-48,370,000USD-25,236,000USD-41,277,000USD149,028,000USD-114,208,000USD
    Sale Purchase Of Stock947,000USD-25,610,000USD25,961,000USD-25,104,000USD506,000USD-25,025,000USD-142,000USD-35,000,000USD
    Change In Cash37,398,000USD81,158,000USD32,748,000USD21,154,000USD20,482,000USD31,605,000USD-108,934,000USD-55,716,000USD
    Begin Period Cash Flow252,158,000USD171,000,000USD137,198,000USD117,094,000USD96,612,000USD65,007,000USD173,941,000USD228,610,000USD
    End Period Cash Flow289,556,000USD252,158,000USD169,946,000USD138,248,000USD117,094,000USD96,612,000USD65,007,000USD172,894,000USD
    Other Cashflows From Financing Activities-15,433,000USD-861,000USD-964,000USD-7,428,000USD-11,148,000USD-106,000USD-142,000USD-39,093,000USD
    Unclassified Operating Cash Flow—-10,072,000USD-12,132,000USD-2,914,000USD—-10,156,000USD-8,733,000USD-3,513,000USD
    Unclassified Financing Cash Flow—26,595,000USD-23,669,000USD—1,552,000USD——-40,115,000USD
    Other Cashflows From Investing Activities——————-267,538,000USD—
    Unclassified Investing Cash Flow——————267,782,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income62,870,000USD69,190,000USD48,155,000USD-25,002,000USD71,517,000USD26,752,000USD-22,722,000USD-39,128,000USD
    Depreciation220,820,000USD169,160,000USD149,256,000USD138,939,000USD68,917,000USD61,550,000USD15,483,000USD110,908,000USD
    Stock Based Compensation41,906,000USD32,400,000USD27,136,000USD22,874,000USD24,255,000USD21,910,000USD16,527,999USD13,778,000USD
    Other Non Cash Items25,624,000USD16,022,000USD30,624,000USD8,523,000USD3,424,000USD9,029,000USD-5,589,999USD19,281,000USD
    Change To Account Receivables17,204,000USD-4,414,000USD3,594,000USD-21,780,000USD-22,524,000USD-10,367,000USD4,993,000USD-68,231,000USD
    Change To Inventory-5,353,000USD13,927,000USD14,169,000USD48,274,000USD-2,296,000USD-8,270,000USD-1,826,000USD219,000USD
    Change In Working Capital3,760,000USD-54,978,000USD21,731,000USD-12,713,000USD13,486,000USD-25,299,000USD24,084,000USD64,551,000USD
    Total Cash From Operating Activities329,323,000USD204,980,000USD274,749,000USD124,230,000USD103,557,000USD93,942,000USD27,783,000USD169,390,000USD
    Capital Expenditures-1,740,000USD-1,652,000USD-461,000USD-1,622,000USD-1,944,000USD-373,772,000USD-6,438,000USD-24,354,000USD
    Free Cash Flow327,583,000USD203,328,000USD274,288,000USD122,608,000USD101,613,000USD-279,830,000USD21,345,000USD145,036,000USD
    Investments-61,792,000USD-287,759,000USD-46,655,000USD-573,691,000USD-1,944,000USD-373,772,000USD-6,438,000USD-24,354,000USD
    Total Cashflows From Investing Activities-63,532,000USD-287,759,000USD-70,812,000USD-573,691,000USD-1,944,000USD-373,772,000USD-6,438,000USD-24,354,000USD
    Net Borrowings-70,383,000USD7,519,000USD-65,918,000USD-75,000,000USD-50,000,000USD281,394,000USD281,394,000USD10,021,000USD
    Total Cash From Financing Activities-110,245,000USD-60,603,000USD-140,178,000USD436,723,000USD-89,303,000USD286,474,000USD2,041,000USD-117,197,000USD
    Sale Purchase Of Stock-25,104,000USD-60,025,000USD-75,000,000USD-14,063,000USD-47,861,000USD-2,255,000USD-822,000USD-560,000USD
    Change In Cash155,546,000USD-143,382,000USD63,759,000USD-12,738,000USD12,310,000USD6,644,000USD23,386,000USD27,839,000USD
    Begin Period Cash Flow96,612,000USD239,994,000USD176,235,000USD188,973,000USD176,663,000USD170,019,000USD146,633,000USD118,794,000USD
    End Period Cash Flow252,158,000USD96,612,000USD239,994,000USD176,235,000USD188,973,000USD176,663,000USD170,019,000USD146,633,000USD
    Other Cashflows From Financing Activities-20,401,000USD-8,097,000USD740,000USD8,104,000USD8,558,000USD5,080,000USD2,863,000USD-127,188,000USD
    Unclassified Operating Cash Flow-25,657,000USD-26,814,000USD—-8,391,000USD-78,042,000USD———
    Unclassified Financing Cash Flow5,643,000USD—9,101,000USD517,682,000USD12,707,000USD9,590,000USD-281,394,000USD—
    Dividends Paid——-9,101,000USD—-12,707,000USD-7,335,000USD——
    Unclassified Investing Cash Flow——-23,696,000USD573,691,000USD1,944,000USD741,998,000USD6,438,000USD43,231,000USD
    Change To Liabilities———-11,838,000USD-1,050,000USD-4,069,000USD-523,000USD26,136,000USD
    Cash And Cash Equivalents Changes———-12,738,000USD12,310,000USD6,644,000USD23,386,000USD27,839,000USD
    Other Cashflows From Investing Activities———-572,069,000USD—-368,226,000USD—-18,877,000USD
    Issuance Of Capital Stock—————0USD——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30ProductAzstarys12,910,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductBelbuca57,669,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductJornay Pm46,058,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductNucynta ER15,723,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductNucynta ERAG2,775,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductNucynta IR14,356,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductNucynta IRAG2,361,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductSymproic3,020,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductXtampza ER45,006,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31ProductBelbuca52,649,000USD0001628280-26-031697
    Q1 2026Quarterly · 2026-03-31ProductJornay Pm38,893,000USD0001628280-26-031697
    Q1 2026Quarterly · 2026-03-31ProductNucynta ER18,233,000USD0001628280-26-031697
    Q1 2026Quarterly · 2026-03-31ProductNucynta ERAG1,446,000USD0001628280-26-031697
    Q1 2026Quarterly · 2026-03-31ProductNucynta IR26,078,000USD0001628280-26-031697
    Q1 2026Quarterly · 2026-03-31ProductNucynta IRAG1,258,000USD0001628280-26-031697
    Q1 2026Quarterly · 2026-03-31ProductSymproic4,194,000USD0001628280-26-031697
    Q1 2026Quarterly · 2026-03-31ProductXtampza ER50,769,000USD0001628280-26-031697
    FY 2025Yearly · 2025-12-31ProductBelbuca221,653,000USD0001628280-26-011992
    FY 2025Yearly · 2025-12-31ProductJornay Pm148,857,000USD0001628280-26-011992
    FY 2025Yearly · 2025-12-31ProductNucynta ER80,985,000USD0001628280-26-011992
    FY 2025Yearly · 2025-12-31ProductNucynta IR115,312,000USD0001628280-26-011992
    FY 2025Yearly · 2025-12-31ProductSymproic And Other14,452,000USD0001628280-26-011992
    FY 2025Yearly · 2025-12-31ProductXtampza ER199,308,000USD0001628280-26-011992
    Q3 2025Quarterly · 2025-09-30ProductBelbuca58,255,000USD0001104659-25-107391
    Q3 2025Quarterly · 2025-09-30ProductJornay Pm41,802,000USD0001104659-25-107391
    Q3 2025Quarterly · 2025-09-30ProductNucynta Er22,813,000USD0001104659-25-107391
    Q3 2025Quarterly · 2025-09-30ProductNucynta Ir31,988,000USD0001104659-25-107391
    Q3 2025Quarterly · 2025-09-30ProductSymproic4,025,000USD0001104659-25-107391
    Q3 2025Quarterly · 2025-09-30ProductXtampza50,478,000USD0001104659-25-107391
    Q2 2025Quarterly · 2025-06-30ProductBelbuca52,600,000USD0001558370-25-010649
    Q2 2025Quarterly · 2025-06-30ProductJornay Pm32,626,000USD0001558370-25-010649
    Q2 2025Quarterly · 2025-06-30ProductNucynta Er19,946,000USD0001558370-25-010649
    Q2 2025Quarterly · 2025-06-30ProductNucynta Ir26,501,000USD0001558370-25-010649
    Q2 2025Quarterly · 2025-06-30ProductSymproic3,722,000USD0001558370-25-010649
    Q2 2025Quarterly · 2025-06-30ProductXtampza52,605,000USD0001558370-25-010649
    Q1 2025Quarterly · 2025-03-31ProductBelbuca51,658,000USD0001628280-26-031697
    Q1 2025Quarterly · 2025-03-31ProductJornay Pm28,539,000USD0001628280-26-031697
    Q1 2025Quarterly · 2025-03-31ProductNucynta ER19,686,000USD0001628280-26-031697
    Q1 2025Quarterly · 2025-03-31ProductNucynta ERAG0USD0001628280-26-031697
    Q1 2025Quarterly · 2025-03-31ProductNucynta IR27,417,000USD0001628280-26-031697
    Q1 2025Quarterly · 2025-03-31ProductNucynta IRAG0USD0001628280-26-031697
    Q1 2025Quarterly · 2025-03-31ProductSymproic2,815,000USD0001628280-26-031697
    Q1 2025Quarterly · 2025-03-31ProductXtampza ER47,642,000USD0001628280-26-031697
    FY 2024Yearly · 2024-12-31ProductBelbuca211,269,000USD0001628280-26-011992
    FY 2024Yearly · 2024-12-31ProductJornay Pm37,239,000USD0001628280-26-011992
    FY 2024Yearly · 2024-12-31ProductNucynta ER75,767,000USD0001628280-26-011992
    FY 2024Yearly · 2024-12-31ProductNucynta IR100,740,000USD0001628280-26-011992
    FY 2024Yearly · 2024-12-31ProductSymproic And Other15,104,000USD0001628280-26-011992
    FY 2024Yearly · 2024-12-31ProductXtampza ER191,330,000USD0001628280-26-011992
    Q3 2024Quarterly · 2024-09-30ProductBelbuca53,197,000USD0001104659-25-107391
    Q3 2024Quarterly · 2024-09-30ProductJornay Pm7,961,000USD0001104659-25-107391
    Q3 2024Quarterly · 2024-09-30ProductNucynta Er19,773,000USD0001104659-25-107391
    Q3 2024Quarterly · 2024-09-30ProductNucynta Ir25,361,000USD0001104659-25-107391
    Q3 2024Quarterly · 2024-09-30ProductSymproic3,517,000USD0001104659-25-107391
    Q3 2024Quarterly · 2024-09-30ProductXtampza49,492,000USD0001104659-25-107391
    Q2 2024Quarterly · 2024-06-30ProductBelbuca52,198,000USD0001558370-25-010649
    Q2 2024Quarterly · 2024-06-30ProductNucynta Er19,272,000USD0001558370-25-010649
    Q2 2024Quarterly · 2024-06-30ProductNucynta Ir25,203,000USD0001558370-25-010649
    Q2 2024Quarterly · 2024-06-30ProductSymproic4,032,000USD0001558370-25-010649
    Q2 2024Quarterly · 2024-06-30ProductXtampza44,571,000USD0001558370-25-010649
    Q1 2024Quarterly · 2024-03-31ProductBelbuca50,663,000USD0001558370-25-006960
    Q1 2024Quarterly · 2024-03-31ProductNucynta Er19,186,000USD0001558370-25-006960
    Q1 2024Quarterly · 2024-03-31ProductNucynta Ir25,960,000USD0001558370-25-006960
    Q1 2024Quarterly · 2024-03-31ProductSymproic3,301,000USD0001558370-25-006960
    Q1 2024Quarterly · 2024-03-31ProductXtampza45,813,000USD0001558370-25-006960
    FY 2023Yearly · 2023-12-31ProductBelbuca182,095,000USD0001628280-26-011992
    FY 2023Yearly · 2023-12-31ProductJornay Pm0USD0001628280-26-011992
    FY 2023Yearly · 2023-12-31ProductNucynta ER82,653,000USD0001628280-26-011992
    FY 2023Yearly · 2023-12-31ProductNucynta IR108,150,000USD0001628280-26-011992
    FY 2023Yearly · 2023-12-31ProductSymproic And Other16,495,000USD0001628280-26-011992
    FY 2023Yearly · 2023-12-31ProductXtampza ER177,374,000USD0001628280-26-011992

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.